The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
出版年份 2015 全文链接
标题
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume 74, Issue 7, Pages 1474-1478
出版商
BMJ
发表日期
2015-02-26
DOI
10.1136/annrheumdis-2014-206016
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
- (2014) M. A. Dimopoulos et al. HAEMATOLOGICA
- Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis
- (2013) Qingyu Cheng et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
- (2013) M. Wang et al. BLOOD
- Carfilzomib
- (2013) K. M. Kortuem et al. BLOOD
- Immunopathogenic mechanisms of systemic autoimmune disease
- (2013) Marie Wahren-Herlenius et al. LANCET
- IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus
- (2012) Thomas Rose et al. ANNALS OF THE RHEUMATIC DISEASES
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Proteasome inhibitor-based therapy for antibody-mediated rejection
- (2012) R. Carlin Walsh et al. KIDNEY INTERNATIONAL
- Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
- (2011) H. Travis Ichikawa et al. ARTHRITIS AND RHEUMATISM
- Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE
- (2011) Matthew M. Seavey et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
- (2011) Falk Hiepe et al. Nature Reviews Rheumatology
- Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
- (2010) M. Hirai et al. BLOOD
- Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus
- (2008) Robert Biesen et al. ARTHRITIS AND RHEUMATISM
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
- (2008) Kirsten Neubert et al. NATURE MEDICINE
- Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
- (2008) Matthew J. Everly et al. TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started